Terlipressin

Also known as triglycyl-lysine-vasopresin

Trade name

Glypressin, Terlipressin (Ever Pharma)

Presentation and preparation

0.1 mg/mL (volume: 8.5 mL)

0.17 mg/mL (volume: 5 mL, 10 mL)

Expressed as terlipressin base.

Terlipressin base 0.85 mg is equivalent to terlipressin acetate 1 mg.

IV administration

Give undiluted as a slow IV injection over at least 3 minutes. 

In certain circumstances and ONLY under specialist advice, can be given over 1 minute.

Flush with sodium chloride 0.9%.

Can be given as an intravenous infusion. Refer to local protocol or guidelines for further information.

Other routes of administration

IM: Not recommended.

SC: Not recommended.

Compatible IV fluids

Sodium chloride 0.9%

Terlipressin 0.05 mg/mL or weaker:

Glucose 5%

Additional information

Extravasation risk.

Use only when facilities for cardiac monitoring and cardio-respiratory resuscitation exist.

Administration may cause serious respiratory failure. Patient should be assessed for oxygenation saturation and monitored during treatment.

Monitor fluid balance and electrolytes. Monitor for signs of ischaemia (coronary, peripheral, mesenteric).

Refrigerate, do not freeze.

Discard any unused vial contents.

Protect from light during storage.